Omnic (Tamsulosin Hydrochloride)

Tamsulosin Hydrochloride, the active ingredient in Omnic, is an alpha‑1 adrenergic antagonist presented as a tablet for oral use. It is used to improve urinary flow in men with benign prostatic hyperplasia. GNH USA supplies Omnic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Omnic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Tamsulosin Hydrochloride is indicated for conditions affecting the lower urinary tract that involve smooth‑muscle tone.

- Benign prostatic hyperplasia (BPH): relieves urinary obstruction and improves urine flow. - Chronic prostatitis: may reduce urinary symptoms associated with prostate inflammation. - Post‑void residual reduction: helps lower residual urine volume after voiding.

Tamsulosin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness, especially on standing. - Abnormal ejaculation, such as reduced volume or retrograde flow. - Nasal congestion or runny nose. - Headache. - Diarrhoea.

Serious or Rare Side Effects: - Severe hypotension or syncope. - Priapism (prolonged painful erection). - Allergic reactions including rash, itching or swelling. - Angio‑edema affecting face, lips or throat.

Before initiating therapy, clinicians should consider several safety aspects.

- Cardiovascular assessment: evaluate for orthostatic hypotension risk. - Concomitant alpha‑blockers: avoid additive blood‑pressure lowering effects. - Liver impairment: use with caution in moderate hepatic dysfunction. - Surgery: inform surgical team as intra‑operative hypotension may occur. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Tamsulosin can interact with other medicines that influence blood pressure or metabolism.

Major Interactions (Avoid): - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): may cause profound hypotension. - Other alpha‑blockers (e.g., doxazosin): additive vasodilatory effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): increase tamsulosin plasma levels. - CYP3A4 inducers (e.g., rifampicin): reduce tamsulosin exposure. - Antihistamines with sedating properties: may enhance dizziness.